Fig. 2

Kaplan Meier curve of cardiovascular events. There was no significant difference between fluoropyrimidines and controls in the incidence of (A) major adverse cardiovascular events (MACE) (HR 0.91, 95% CI: 0.70–1.18, p = 0.46), (B) cardiovascular death (HR 1.05, 95% CI: 0.69–1.60, p = 0.82), (C) myocardial infarction (HR 0.73, 95% CI: 0.50–1.25, p = 0.25), (D) ischemic stroke (HR 0.89, 95% CI: 0.64–1.24, p = 0.49), (E) new-onset atrial fibrillation (HR 0.75, 95% CI: 0.49–1.14, p = 0.18), or (F) ventricular tachyarrhythmia (HR 1.31, 95% CI 0.29–5.84, p = 0.73). Abbreviation: Hazard ratio, HR; 95% confidence interval, 95% CI